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ABSTRACT
Introduction: To assess the long-term safety
and efficacy of subcutaneous tocilizumab
(TCZ-SC) in US patients with rheumatoid
arthritis (RA) who rolled over from the two
global phase 3 studies, SUMMACTA
(NCT01194414) and BREVACTA
(NCT1232569), into this open-label,
single-arm, phase 3b study.
Methods: Patients continued to receive TCZ-SC
162 mg weekly or every other week or switched
from intravenous TCZ to TCZ-SC 162 mg qw for
up to 84 weeks. The primary endpoint was the
proportion of patients with serious adverse
events (SAEs). Secondary endpoints included
clinical efficacy, laboratory abnormalities, and
immunogenicity.
Results: Of the 217 patients treated, 76.5%
were female, and the mean age was 58.4 years.
A total of 23 patients (10.6%) had C1 SAE. The
most common SAEs were infections (3.7%).
Alanine aminotransferase elevations (38.2%)
were not associated with hepatic injury. Grade
3/4 neutropenia (3%) was transient and not
associated with serious infections.
Immunogenicity was low (\1%) and not
associated with SAEs. No anaphylaxis or
deaths occurred. Thirteen patients (6.0%)
withdrew due to safety reasons. Mean Clinical
Disease Activity Index and Disease Activity
Score in 28 joints remained stable throughout
the trial.
Conclusions: The long-term safety of TCZ-SC
during the long-term extension period was
consistent with the safety profiles from
SUMMACTA and BREVACTA, with no new
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safety signals. Efficacy improvements observed
from baseline remained stable over time. These
results demonstrated the durability of the safety
and efficacy responses, and low
immunogenicity, with long-term exposure to
TCZ-SC in patients with RA.
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Trial registration number: ClinicalTrials.gov
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic,
progressive autoimmune disease characterized
by inflammation of the joints that, if left
untreated, leads to irreversible joint damage
and disability. Biologic disease-modifying
antirheumatic drugs (bDMARDs) that block
inflammatory cytokines, B cells, or T cells are
commonly used for the treatment of RA in
combination with conventional synthetic
DMARDs (csDMARD) or as monotherapy. Due
to the long-term treatment of patients with RA
with bDMARDs, it is important to establish that
these drugs have lasting efficacy and safety.
Tocilizumab (TCZ) is the first drug approved
for the treatment of RA that blocks the
biological activity of interleukin 6 (IL-6). TCZ
is a humanized monoclonal antibody that
competitively interferes with the binding of
IL-6 to the IL-6 receptor (IL-6R, also known as
IL-6Ra or CD126), thereby disrupting receptor
association with glycoprotein 130, a co-signal
transducer protein (also known as IL-6Rb or
CD130) necessary for initiating intracellular
signaling through the JAK-STAT and other
pathways [10]. TCZ, in combination with
csDMARDs or as monotherapy, has
demonstrated efficacy with a well-established
safety profile in patients with RA who had an
inadequate response to csDMARDs or
anti-tumor necrosis factor agents (aTNFs)
[2, 4–6]. Intravenous [IV; 4 and 8 mg/kg every
4 weeks (q4w)] and subcutaneous [SC; 162 mg
weekly (qw) or every 2 weeks (q2w)]
formulations of TCZ are available for the
treatment of patients with RA.
The efficacy and safety of TCZ-SC was
demonstrated in two recent global phase 3
clinical trials in patients with RA who had an
inadequate response to csDMARDs or aTNFs:
BREVACTA (NCT1232569) reported the
superiority of TCZ-SC q2w plus csDMARDs to
placebo SC plus csDMARDs over 24 weeks [8].
SUMMACTA (NCT01194414) reported the
noninferiority of TCZ-SC qw to TCZ-IV 8 mg/
kg q4w, in combination with a csDMARDs, over
24 weeks [7]. The extensions of SUMMACTA
and BREVACTA with TCZ-SC qw and TCZ-SC
q2w, respectively, to 96–97 weeks demonstrated
that efficacy and safety remained comparable to
the known profile of TCZ-IV [9]. Additionally,
the MUSASHI (JapicCTI-101117) trial in Japan
reported the noninferiority of TCZ-SC q2w as
monotherapy to TCZ-IV 8 mg/kg q4w as
monotherapy in patients who had an
inadequate response to methotrexate or a
bDMARD over a 24-week study period; the
continued efficacy and safety of TCZ-SC
monotherapy in MUSASHI has been reported
out to 2 years [1, 11].
This open-label long-term extension phase
3b study for up to an additional 84 weeks
evaluated the long-term safety,
immunogenicity, and efficacy of TCZ-SC in
patients in the US who completed the
SUMMACTA or BREVACTA studies.
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METHODS
Participants
The study population consisted of adult
patients (C18 years of age) with RA
(C6 months) in the United States who had
moderate-to-high disease activity and
completed SUMMACTA [7] or BREVACTA [8]
and, on the basis of the investigator’s judgment,
might have continued to benefit from TCZ-SC
treatment.
Study Design
This was a multicenter phase 3b long-term
extension study of SUMMACTA and BREVACTA
(Figure S1 in the supplementary material; trial
registration number NCT01662063). For
enrollment in both SUMMACTA and
BREVACTA, patients (C18 years of age) with RA
(C6 months, revised 1987 American College of
Rheumatology criteria) were included and were
required to have had an inadequate response to
C1 DMARD (up to 20% of patients may have had
inadequate response to C1 aTNF). Patients who
completed the 96–97-week BREVACTA and
SUMMACTA studies and met the enrollment
criteria continued to receive TCZ-SC q2w or
TCZ-SC qw, respectively, or switched from
TCZ-IV to TCZ-SC 162 mg qw for up to an
additional 84 weeks. Thus, all patients in the
long-term extension were receiving TCZ-SC.
Baseline was defined as the beginning of this
long-term extension for all efficacy and safety
data. Study treatment at baseline was given at
least 6 weeks after the last TCZ-IV dose or at least
4 weeks after the last TCZ-SC dose. The
maximum interval allowed between the last
dose in the core study and initiation of




anti-inflammatory drugs were permitted up to
the maximum dose based on clinical response
and the physician’s judgment (Figure S2 in the
supplementary material).
The end of the study occurred up to 84 weeks
of treatment because the SC formulation of TCZ
was approved by the US Food and Drug
Administration and commercial supplies
became available as planned.
Outcomes and Assessments
The primary study endpoint was the number
and percentage of patients with serious adverse
events (SAEs) during long-term treatment with
TCZ-SC. The secondary safety endpoints were
the number and percentage of patients who
experienced AEs of special interest, number and
percentage of patients with AEs and SAEs
causing discontinuation of TCZ, number and
percentage of patients who discontinued TCZ
for any reason, incidence of clinically
significant laboratory abnormalities
(hematology, lipid profiles, and liver function),
rates of immunogenicity, summary of abnormal
vital signs, and patient compliance (drug
dispensing logs, patient diary cards, and return
records). Clinical efficacy was measured by the
Disease Activity Score in 28 joints using the
erythrocyte sedimentation rate (DAS28-ESR),
Clinical Disease Activity Index (CDAI),
Simplified Disease Activity Index (SDAI), total
tender joint count (TJC), total swollen joint
count (SJC), and achievement of Boolean
remission (defined as SJC B1, TJC B1, patient
global assessment visual analog scale score
B1 cm, and C-reactive protein level B1 mg/dL).
AEs were monitored throughout the study,
and laboratory measurements were assessed every
12 weeks. Efficacy assessments were made every
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12 weeks. Blood samples were collected to
evaluate TCZ and soluble IL-6R serum levels
and development of anti-TCZ antibodies
(Figure S3 in the supplementary material).
Statistical Methods
No formal statistical hypothesis testing was
performed. Patients were grouped by their initial
dose frequency. Safety analyses included all
patients who received C1 dose of study
medication and had C1 postdose safety
assessment. Efficacy analyses included all patients
who receivedC1doseof studymedication andhad
C1 efficacy measurement performed. Due to the
noncomparative nature of the study, descriptive
statistics were produced for all endpoints.
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional review boards: Southern Arizona
VA Health Care System, St. Vincent Hospital/
Reliant Medical Group/Fallon Community
Health Plan, Western, Oklahoma Medical
Research Foundation, Via Christi Hospitals
Wichita, Inc. and Dartmouth Hitchcock
Medical Center Quorum) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients included in the study.
RESULTS
Patient Disposition and Baseline
Characteristics
A total of 217 patients who completed
BREVACTA or SUMMACTA were enrolled and
received treatment, including 44 patients who
received TCZ-SC q2w and 173 patients who
received TCZ-SC qw (Fig. 1). Of the 217
patients, 183 (84.3%) completed the study at
the time of TCZ-SC formulation approval. The
mean length of TCZ-SC additional exposure was
0.93 years past the original 96-week 2-year
studies. The integrated mean duration of
TCZ-IV or TCZ-SC exposure (the duration in
the core studies combined with the duration in
this study) was 2.6 years.
Baseline demographics and clinical
characteristics were balanced across the dosing
frequency groups (Table 1). The majority of
patients (76.5%) were female, and the mean
[standard deviation (SD)] age was 58.4 (10.3)
years. The mean (SD) duration of RA was 12.8
(9.0) years, the mean (SD) CDAI was 23.1 (16.2),
the mean (SD) DAS28 was 4.6 (1.9), and the
mean (SD) SDAI was 24.4 (16.8).
Safety
The rates of AEs and SAEs were stable over time
in both TCZ-SC qw and TCZ-SC q2w dosing
groups (Table 2). A total of 179 patients (82.5%)
experienced 954 AEs (133 AEs in the TCZ-SC
q2w group and 821 AEs in the TCZ-SC qw
group). The most common AEs for all patients
were upper respiratory tract infection (19.8%),
sinusitis (11.1%), and nasopharyngitis (10.1%).
A total of 23 patients (10.6%) experienced 37
SAEs (7 SAEs in the TCZ-SC q2w group and 30
SAEs in the TCZ-SC qw group). The rate of SAEs
was 14.72 events per 100 patient-years (PY), and
the most common SAEs for all patients were
infections (3.7%), nervous system disorders
(2.3%), gastrointestinal (GI) disorders (1.8%),
and musculoskeletal and connective tissue
disorders (1.8%). There were no deaths.
There were 85 patients (49.1%) in the
TCZ-SC qw group and 12 patients (27.3%) in
the TCZ-SC q2w group who experienced AEs
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leading to dose modification or interruption.
Seven patients (3.2%) had their dosing
frequency reduced from TCZ-SC qw to TCZ-SC
q2w due to AEs. Withdrawals occurred in 15.7%
of patients, with 6.0% of patients withdrawing
due to safety reasons (2.3% in the TCZ-SC q2w
group and 6.9% in the TCZ-SC qw group).
There were 11 serious infections in eight
patients (4.38 per 100 PY), and there were no
opportunistic infections (Table 2). The serious
infections reported in the TCZ-SC qw group
included cellulitis (3 events), septic arthritis (1
event), endocarditis (1 event), staphylococcal
bacteremia (2 events), and bronchopneumonia
(1 event). In the TCZ-SC q2w group,
endophthalmitis (1 event) and pyelonephritis
(2 events) were reported. There were two GI
perforation events in the TCZ-SC qw group and
no GI perforation events in the TCZ-SC q2w
group. One GI perforation event was a
diverticular perforation considered related to
study treatment and the other was a gastric
ulcer perforation complicated by peritonitis.
There were no myocardial infarctions,
demyelinating disorders, or serious hepatic
events. There were a total of five strokes, all in
the TCZ-SC qw group. One patient in the
TCZ-SC q2w group experienced a serious
bleeding event (hematuria). There were two
malignancies, one in the TCZ-SC q2w group
(basal cell carcinoma) and one in the TCZ-SC
qw group (endometrial stromal sarcoma).
Hypersensitivity Reactions, Injection Site
Reactions and Immunogenicity
There were six non-serious hypersensitivity
reactions defined as all AEs [except for
injection site reactions (ISRs)] that occurred
Fig. 1 Overview of patient disposition. aOne patient was
not treated. bFourteen patients did not meet the screening
criteria including unable and unwilling to provide written
informed consent and to comply with the requirements of
the study protocol; any major episode of infection
requiring hospitalization or treatment with intravenous
antibiotics B4 weeks of screening or oral antibiotics
B2 weeks of screening; receiving intraarticular or
parenteral corticosteroids B4 weeks prior to baseline;
diagnosed with neuropathies or other conditions that might
interfere with pain evaluation; and meeting any lab
exclusion criteria at screening (i.e., alanine aminotransferase
or aspartate aminotransferase [3 times upper limit of
normal (ULN), total bilirubin[ULN). Fifteen patients did
not enroll in the long-term extension due to either the
physicians’ recommendations or personal decisions not to
participate. AE adverse event; qw every week, q2w every
2 weeks, SC subcutaneous, TCZ tocilizumab
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during or within 24 h of injection and which
were not judged ‘unrelated’ to treatment by the
investigator, regardless of whether or not they
were consistent with hypersensitivity. There
were 29 ISRs in six patients during the study
(one patient in the TCZ-SC q2w group and five
patients in the TCZ-SC qw group; Table 3).
None of the ISRs in any patient was serious,
and none of the patients discontinued study
treatment due to an ISR. One patient had 24
ISRs. In this patient, ISRs occurred with every
TCZ-SC qw injection up to 216 study days, and
there were no reports of ISRs &4 months after
reducing the dose frequency to TCZ-SC q2w;
the patient did not discontinue treatment and
no clinical sequelae were associated with the
ISRs. This patient experienced ISRs with every
injection in the core trial as well.
One patient developed antidrug antibodies
in the TCZ-SC qw arm (Table 3). No patients
experienced anaphylaxis, serious
hypersensitivity, or clinically significant
hypersensitivity reactions, including the one
who developed anti-TCZ antibodies. There was
no association between lack of efficacy or loss of
therapeutic response and development of







Female, n (%) 33 (75.0) 133 (76.9) 166 (76.5)
Age, mean (SD), years 59.7 (10.2) 58.1 (10.4) 58.4 (10.3)
Duration of RA, mean (SD), years 13.8 (10.1) 12.5 (8.7) 12.8 (9.0)
Weight, mean (SD), kg 77.4 (20.9) 85.2 (22.2) 83.6 (22.1)
BMI, mean (SD), kg/m2 29.2 (7.3) 31.3 (7.7) 30.9 (7.6)
DAS28-ESR, mean (SD) 4.6 (1.7) 4.6 (1.9) 4.6 (1.9)
CDAI, mean (SD) 20.1 (15.5) 23.9 (16.4) 23.1 (16.2)
SDAI, mean (SD) 21.5 (15.7) 25.1 (17.0) 24.4 (16.8)
CRP, mean (SD), mg/dL 1.4 (2.3) 1.1 (1.8) 1.2 (1.9)
ESR, mean (SD), mm/h 34.1 (31.0) 29.0 (25.5) 30.0 (26.7)
Tender joints (68-joint count), mean (SD) 13.8 (13.9) 19.1 (18.5) 18.1 (17.7)
Swollen joints (66-joint count), mean (SD) 9.1 (8.9) 10.8 (10.9) 10.5 (10.5)
Physician’s global assessment of disease activity, mean (SD) 30.7 (24.2) 38.1 (26.4) 36.6 (26.1)
Patient’s global assessment of disease activity, mean (SD) 39.4 (24.5) 47.3 (29.9) 45.7 (29.0)
Patient’s global assessment of pain activity, mean (SD) 36.9 (23.0) 45.4 (29.5) 43.7 (28.4)
HAQ-DI, mean (SD) 1.0 (0.7) 1.2 (0.7) 1.2 (0.7)
a Data represent the baseline patient characteristics at the start of the 84-week long-term extension. Study treatment at
baseline was given at least 6 weeks after the last TCZ-IV dose or at least 4 weeks after the last TCZ-SC dose. Baseline
DAS28, CDAI and SDAI are from the last assessment before the ﬁrst dose of study medication in the long-term extension
BMI body mass index, CDAI clinical disease activity index, CRP C-reactive protein, DAS28-ESR disease activity score in 28
joints based on the erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire—Disability Index, qw every
week, q2w every 2 weeks, RA rheumatoid arthritis, SC subcutaneous, SD standard deviation, SDAI simpliﬁed disease activity
index, TCZ tocilizumab
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Total AEsa 133 821 954
AEs per 100 PY (95% CI) 334.9 (280.4–396.9) 388.1 (362.0–415.5) 379.7 (356.0–404.5)
Patients with C1 AE, n (%) 33 (75.0) 146 (84.4) 179 (82.5)
Led to dose modiﬁcation/interruption, n (%)a 12 (27.3) 85 (49.1) 97 (44.7)
Led to discontinuation, n (%)a 2 (4.5) 14 (8.1) 16 (7.4)
SAEs
Total SAEsa 7 30 37
SAEs per 100 PY (95% CI) 17.6 (7.1–36.3) 14.2 (9.6–20.2) 14.7 (10.4–20.3)
Patients with C1 SAE, n (%) 4 (9.1) 19 (11.0) 23 (10.6)
Serious infections per 100 PY (95% CI) 7.6 (1.6–22.1) 3.8 (1.6–7.5) 4.4 (2.2–7.8)
Led to dose modiﬁcation/interruption, n (%)a 1 (2.3) 9 (5.2) 10 (4.6)
Led to discontinuation, n (%)a 2 (4.5) 7 (4.0) 9 (4.1)
SAEs by type, no. of events
Serious infections 3 8 11
Opportunistic infections 0 0 0
Myocardial infarction/acute coronary syndrome 0 0 0
Stroke 0 5 5
Serious bleeding event 1 0 1
Gastrointestinal perforations
Diverticular perforations 0 1 1
Gastric ulcer perforationsb 0 1 1
Malignancies
Basal cell carcinomac 1 0 1
Endometrial stromal sarcoma 0 1 1
Demyelinating disorders 0 0 0
Serious hepatic events 0 0 0
Withdrawals
Total, n (%) 5 (11.4) 29 (16.8) 34 (15.7)
Due to safety reasons, n (%) 1 (2.3) 12 (6.9) 13 (6.0)
Due to nonsafety reasons, n (%) 4 (9.1) 17 (9.8) 21 (9.7)
AE adverse event, CI conﬁdence interval, PY patient-year, qw every week, q2w every 2 weeks, SAE serious adverse event, SC
subcutaneous, TCZ tocilizumab
a Multiple occurrences of the same AE in the same individual were counted
b This patient had a gastric ulcer perforation complicated by peritonitis
c This was a non-serious event
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anti-TCZ antibodies. None of the patients who
withdrew due to insufficient therapeutic
response had a positive anti-TCZ antibody
screening assay.
Laboratory Abnormalities
The overall incidence of markedly abnormal
laboratory values was B5%. Elevations[3 9 the
upper limit of normal (ULN) at any point in
alanine aminotransferase (ALT) levels were
observed in two patients and in aspartate
aminotransferase levels were observed in one
patient (Table 4). Two patients in the TCZ-SC
qw group had C2 consecutive observations of
ALT[3 9 ULN. No serious hepatic events were
observed in any patients. There were six cases of
grade 3 neutropenia (C500 to\1000 cells/mm3)
reported as AEs (one in the TCZ-SC q2w group
and five in the TCZ-SC qw group). No patients
who experienced neutropenia developed
serious or opportunistic infections. One
patient in the TCZ-SC qw group experienced
grade 3 thrombocytopenia (C50,000 to\25,000
cells/mm3) that was reported as an SAE. Among
the patients with normal cholesterol levels at
baseline, there were nine grade 1 levels ([ULN
to B7.75 mmol/L; 2 in the TCZ-SC q2w group
and 7 in the TCZ-SC qw group) and 18 grade 2
levels ([7.75 to B10.34 mmol/L; all in the
TCZ-SC qw group). Among patients with
normal triglyceride levels as baseline, there
were 28 grade 1 ([1.71 to B3.42 mmol/L), 1
grade 2 ([3.42 to B5.7 mmol/L) and 1 grade 3
([5.7 to B11.4 mmol/L) levels. Seven patients
(3%) had markedly high (C5.4 mmol/L) low
density lipoprotein cholesterol levels, all of
whom were in the TCZ-SC qw group.
Efficacy
The efficacy of TCZ remained stable over time.
Mean DAS28-ESR, CDAI, and SDAI scores
decreased from baseline and then remained
stable over time (Fig. 2a and Figure S4 in the
supplementary material). At the time the study
ended due to the SC formulation of TCZ








No. of patients with injection site reaction 1 5 6
Injection site reactionsa 1 28 29
Hypersensitivity reactions 0 6 6
Anaphylaxis 0 0 0
Immunogenicity
No. of patients tested by screening at any time point 44 166 210
Positive conﬁrmation assay, n (%) 0 1 (0.6) 1 (0.5)
Positive neutralizing assay, n (%) 0 1 (0.6) 1 (0.5)
a Six patients experienced 29 injection site reactions during the study (one patient in the q2w group and ﬁve patients in qw
group). None of the injection site reactions in any patient were serious, and none of the patients were withdrawn from study
treatment due to an injection site reaction. One patient experienced 24 injection site reactions during the study
qw every week, q2w every 2 weeks, SC subcutaneous, TCZ tocilizumab
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Table 4 Laboratory Abnormalities
TCZ-SC q2w (N5 44) TCZ-SC qw (N5 173) All patients (N5 217)
ALT levels, n (%)a n = 38 n = 135 n = 173
[ULN 8 (21.1) 58 (43.0) 66 (38.2)
[19 to 29 ULN 7 (18.4) 48 (35.6) 55 (31.8)
[29 to 39 ULN 0 9 (6.7) 9 (5.2)
[39 ULN 1 (2.6) 1 (0.7) 2 (1.2)
AST levels, n (%)b n = 38 n = 146 n = 184
[ULN 8 (21.1) 42 (28.8) 50 (27.2)
[19 to 29 ULN 8 (21.1) 39 (26.7) 47 (25.5)
[29 to 39 ULN 0 3 (2.1) 3 (1.6)
[39 ULN 0 1 (0.7) 1 (0.5)c
Neutropenia, n (%)d n = 41 n = 158 n = 199
Grade 1 8 (19.5) 23 (14.6) 31 (15.6)
Grade 2 3 (7.3) 15 (9.5) 18 (9.0)
Grade 3 1 (2.4) 5 (3.2) 6 (3.0)
Grade 4 0 0 0
Thrombocytopenia, n (%)e n = 43 n = 170 n = 213
Grade 1 4 (9.3) 20 (11.8) 24 (11.3)
Grade 2 0 0 0
Grade 3 0 1 (0.6) 1 (0.5)
Grade 4 0 0 0
Cholesterol, n (%)f n = 41 n = 152 n = 193
Grade 1 2 (4.9) 7 (4.6) 9 (4.7)
Grade 2 0 18 (11.8) 18 (9.3)
Grade 3 0 0 0
Grade 4 0 0 0
Triglycerides, n (%)g n = 39 n = 141 n = 180
Grade 1 5 (12.8) 23 (16.3) 28 (15.6)
Grade 2 0 1 (0.7) 1 (0.6)
Grade 3 0 1 (0.7) 1 (0.6)
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becoming commercially available, only two and
one patients from the TCZ-SC q2w group
remained up to 60 and 72 weeks, respectively;
therefore, the efficacy for this group beyond
60 weeks cannot be accurately evaluated.
Overall, the proportion of patients who
achieved low disease activity (LDA) and
remission based on DAS28-ESR (defined as
DAS28-ESR B 2.6 and DAS28-ESR B3.2,
respectively) at 36 weeks in the extension
period, after which there was not a sufficient
number of patients for analysis, was 48.5% and
36.4%, respectively (Fig. 2b; results by group are
shown in Fig. 2c, d). A total of 62.0% of patients
achieved an ACR20 response at week 36 of the
extension period. Based on CDAI, LDA and
remission at 36 week of the extension period
were achieved in 40.9% and 11.1% of patients,
respectively, and based on SDAI, LDA and
remission at 36 weeks in the extension period
were achieved in 40.9% and 14.1% of patients,
respectively. Four patients (1.8%) had their
dosing frequency reduced from TCZ-SC qw to
TCZ-SC q2w due to sustained clinical remission.
Pharmacokinetics
and Pharmacodynamics
The mean concentration of serum TCZ in
patients in the TCZ-SC qw treatment group
increased from baseline (the beginning of the
extension period) to week 12, then remained
constant until week 72, ranging between 36.6
and 40.4 lg/mL. The mean concentration of
serum TCZ in patients in the TCZ-SC q2w
treatment group increased from baseline to
week 48, ranging between 8.4 and 15.9 lg/mL.
The mean soluble IL-6R concentration in
patients receiving TCZ-SC qw increased from
baseline to week 12, then stayed constant until
week 72, and post baseline, the concentration
ranged between 523.2 and 579.4 ng/mL. The
mean soluble IL-6R concentration in patients
receiving TCZ-SC q2w steadily increased from
Table 4 continued
TCZ-SC q2w (N5 44) TCZ-SC qw (N5 173) All patients (N5 217)
Grade 4 0 0 0
a Denominator is the number of patients who had normal ALT levels at baseline and C1 postbaseline value
b Denominator is the number of patients who had normal AST levels at baseline and C1 postbaseline value
c This patient had AST levels 19 to 29 ULN at baseline
d Denominator is the number of patients who had normal neutrophil counts (grade 0) at baseline and C1 postbaseline
value. Neutropenia grades were deﬁned as follows: grade 1,\lower limit of normal to C1500 cells/mm3; grade 2, C1000 to
\1500 cells/mm3; grade 3, C500 to\1000 cells/mm3; grade 4,\500 cells/mm3
e Denominator is the number of patients who had normal platelet counts (grade 0) at baseline and C1 postbaseline value.
Thrombocytopenia grades were deﬁned as follows: grade 1,\lower limit of normal to C75,000 cells/mm3; grade 2, C75,000
to\50,000 cells/mm3; grade 3, C50,000 to\25,000 cells/mm3; grade 4,\25,000 cells/mm3
f Denominator is the number of patients who had normal cholesterol levels (grade 0) at baseline. Cholesterol grades were
deﬁned as follows: grade 1, [ULN to B7.75 mmol/L; grade 2, [7.75 to B10.34 mmol/L; grade 3, [10.34 to
B12.92 mmol/L;[12.92 mmol/L
g Denominator is the number of patients who had normal triglyceride levels (grade 0) at baseline. Triglyceride grades were
deﬁned as follows: grade 1,[1.71 to B3.42 mmol/L;[3.42 to B5.7 mmol/L; grade 3,[5.7 to B11.4 mmol/L; grade 4,
[11.4 mmol/L
ALT alanine aminotransferase, AST aspartate aminotransferase, qw every week, q2w every 2 weeks, SC subcutaneous, TCZ
tocilizumab, ULN upper limit of normal
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baseline to week 48, and from week 12 to
week 48, the concentration ranged between
398.7 and 518.9 ng/mL.
DISCUSSION
This long-term extension of the SUMMACTA
and BREVACTA studies assessed the safety,
immunogenicity, and efficacy of the extended
use of TCZ-SC qw and TCZ-SC q2w in US
patients with RA. The long-term use of TCZ-SC
was well tolerated and consistent with the
known safety profile of TCZ. The rate of SAEs
(events/100 PY) in this study was 14.7,
consistent with the rates observed for TCZ-SC
at 96 or 97 weeks in BREVACTA and
SUMMACTA [11.2 events/100 PY (TCZ-SC
q2w) and 14.6 events/100 PY (TCZ-SC qw),
respectively] [9]. Serious infections were the
most common SAE, and the overall incidence of
serious infections in this study (4.38/100 PY)
was similar to that in previous TCZ studies,
including the 97-week SUMMACTA trial (3.95/
100 PY for TCZ-SC qw and 3.92/100 PY for
Fig. 2 Efﬁcacy over time. Time is shown in weeks from
the beginning of the extension study; total TCZ exposure
time is the indicated extension study week plus 96 or
97 weeks from the core trial. Mean (95% CI) DAS28-ESR
in patients who received TCZ-SC qw or TCZ-SC q2w
(total patients) is shown for each 12 week interval during
the study (a). The percentage of patients in DAS28 LDA
or remission is shown over the course of the study for the
total population (b) and those who received TCZ-SC q2w
(c) or TCZ-SC q2w (d). Remission was deﬁned as DAS28
B2.6 and LDA was deﬁned as DAS28 B3.2. CI conﬁdence
interval, LDA low disease activity, SC subcutaneous, TCZ
tocilizumab, qw weekly, q2w every other week,
DAS28-ESR disease activity score in 28 joints using the
erythrocyte sedimentation rate
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TCZ-IV q4w), the long-term cumulative safety
analyses of the phase 3 TCZ-IV clinical trials
(4.5/100 PY), and the 3-year postmarketing
report of TCZ-IV in Japan (3.67/100 PY)
[3, 9, 12]. No new safety signals were identified.
Immunogenicity is a concern with biologic
therapies. Antidrug antibodies can lead to loss
of efficacy, hypersensitivity reactions, and/or
allergic responses [13, 14]. In this long-term
extension study of TCZ-SC, immunogenicity
was very low, which was consistent with
previous studies of TCZ-SC and TCZ-IV.
[7, 9, 11, 15] Only one patient (0.5%)
developed anti-TCZ antibodies, and this
patient did not experience anaphylaxis, serious
hypersensitivity reactions, or ISRs. Moreover,
this patient did not experience a lack of efficacy
or loss of therapeutic response associated with
the development of anti-TCZ antibodies.
Similarly, in the 97-week SUMMACTA study in
which patients received TCZ-SC or TCZ-IV,
0.5–1.6% of patients developed anti-TCZ
antibodies, with no correlation between
anti-TCZ antibody development and clinical
response or AEs [9]. This and other studies have
shown that TCZ has one of the lowest
incidences of antidrug antibody development
among bDMARDs [16, 17], even lower than
what has recently been reported for a fully
human monoclonal antibody against the IL-6R
[18].
Overall, the efficacy data in this study
showed benefit of the extended use of TCZ-SC,
given that patients who remained in the study
and continued to receive TCZ-SC remained
stable from baseline in mean DAS28-ESR,
CDAI, and SDAI. The proportion of patients
who achieved LDA increased or remained
stable with the continuation of TCZ-SC
treatment. Improvements in patient’s and
physician’s global assessment of disease
activity and pain were also maintained over
time with the extended use of TCZ-SC.
There were some limitations to this analysis.
Whereas SUMMACTA and BREVACTA were
global studies, this long-term extension of
SUMMACTA and BREVACTA was conducted
only in US patients. Despite this difference,
the safety and efficacy profiles in this study were
comparable with those in the global studies.
Overall, the number of patients was low
(N = 217), with only 44 patients in the TCZ-SC
q2w group. In addition, this extension study
was limited to patients who completed
SUMMACTA and BREVACTA; those who
discontinued for any reason, including due to
safety or efficacy, were not included. Only 14
patients (6.5%) reduced dosing frequency from
TCZ-SC qw to TCZ-SC q2w (7 patients reduced
due to AEs and four patients reduced due to
sustained remission); therefore, this study
provided limited additional information
concerning the patients who received less
frequent dosing.
CONCLUSION
In this long-term extension analysis to the
SUMMACTA and BREVACTA trials, the
long-term use of TCZ-SC showed no increased
risk of safety events and efficacy was maintained
or improved. Overall, the results of this study
supported the long-term safety and efficacy of
TCZ-SC qw or TCZ-SC q2w therapy in patients
with RA.
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